| abstract |
Described herein are compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof:n n n [Formula I]n n n n n n n n In Formula I,n n n X is -O-, -C (R 14 ) 2 -or -N (R)-;n n n Z is -C (R 14 ) 2 -or -N (R)-;n n n t is 0, 1, 2 or 3;n n n Each R and R 2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl;n n n Each R 14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, hetero arylalkyl, heterocycloalkylalkyl , -OR 35 , -N (R 24 ) (R 25 ) or -SR 35 ;n n n R 41 is alkyl, cycloalkyl, —SO (alkyl), —C (O) -alkyl, —C (O) -cycloalkyl or —aryl-NH—C (O) CH 3 ;n n n The remaining variables are as defined in the specification.n n n Also described are pharmaceutical compositions and methods of treatment useful for treating cognitive impairment or neurodegenerative diseases, including compounds of formula (I) and other agents. |